TGFβ can stimulate the p38/β-catenin/PPARγ signaling pathway to promote the EMT, invasion and migration of non-small cell lung cancer (H460 cells)

Clinical and Experimental Metastasis

Volumn 31, Issue 8, 2014, Pages 881-895

  Lin, Li Chiung ^a   Hsu, Shih Lan ^b   Wu, Chieh Liang ^b   Hsueh, Chi Mei ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

EMT; H460 cells; NSCLCs; PPAR ; TGF ; Tumor invasion; Tumor migration; catenin

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2,4 DIAMINOQUINAZOLINE DERIVATIVE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BETA CATENIN; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; JW 67; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN INHIBITOR; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; MITOGEN ACTIVATED PROTEIN KINASE P38; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CH27 CELL LINE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSFECTION; GLIOMA CELL LINE; H460 CELL LINE; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; U373 CELL LINE; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOPRECIPITATION; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOPRECIPITATION; LUNG NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PPAR GAMMA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 84916880042     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-014-9677-y     Document Type: Article

References (50)

1. Bennett WP, el-Deiry WS, Rush WL, Guinee DG Jr, Freedman AN, Caporaso NE, Welsh JA, Jones RT, Borkowski A, Travis WD, Fleming MV, Trastek V, Pairolero PC, Tazelaar HD, Midthun D, Jett JR, Liotta LA, Harris CC (1998) p21waf1/cip1 and transforming growth factor β1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res 4:1499–1506
2. Bikkavilli RK, Feigin ME, Malbon CC (2008) p38 mitogen-activated protein kinase regulates canonical Wnt-β-catenin signaling by inactivation of GSK3β. J Cell Sci 121:3598–3607
3. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T (2005) Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and β-catenin. Cells Tissues Organs 179:56–65
4. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, Nemenoff RA (2005) Peroxisome proliferators-activated receptor γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 24:1412–1422
5. Chen Z, Venkatesan AM, Dehnhardt CM, Dos Santos O, Delos Santos E, Ayral-Kaloustian S, Chen L, Geng Y, Arndt KT, Lucas J, Chaudhary I, Mansour TS (2009) 2,4-Diamino-quinazolines as inhibitors of β-catenin/Tcf-4 pathway: potential treatment for colorectal cancer. Bioorg Med Chem Lett 19:4980–4983
6. Choi IK, Kim YH, Kim JS, Seo JH (2008) PPARγ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo. Invest New Drugs 26:283–288
7. Chow G, Tauler J, Mulshine JL (2010) Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer. J Biomed Biotechnol 2010:485468
8. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA (1998) The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis 19:49–53
9. Eger A, Stockinger A, Park J, Langkopf E, Mikula M, Gotzmann J, Mikulits W, Beug H, Foisner R (2004) β-catenin and TGFβ signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene 23:2672–2680
10. Endo Y, Suzuki M, Hamada H, Horita S, Kunimi M, Yamazaki O, Shirai A, Nakamura M, Iso-O N, Li Y, Hara M, Tsukamoto K, Moriyama N, Kudo A, Kawakami H, Yamauchi T, Kubota N, Kadowaki T, Kume H, Enomoto Y, Homma Y, Seki G, Fujita T (2011) Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling. Cell Metab 13:550–561
11. Fischer AN, Herrera B, Mikula M, Proell V, Fuchs E, Gotzmann J, Schulte-Hermann R, Beug H, Mikulits W (2005) Integration of Ras subeffector signaling in TGFβ mediated late stage hepatocarcinogenesis. Carcinogenesis 26:931–942
12. Giaginis C, Politi E, Alexandrou P, Sfiniadakis J, Kouraklis G, Theocharis S (2012) Expression of Peroxisome proliferator activated receptor-gamma (PPAR-γ) in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients’ survival. Pathol Oncology Res 18:875–883
13. Girnun GD, Chen L, Silvaggi J, Drapkin R, Chirieac LR, Padera RF, Upadhyay R, Vafai SB, Weissleder R, Mahmood U, Naseri E, Buckley S, Li D, Force J, McNamara K, Demetri G, Spiegelman BM, Wong KK (2008) Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res 14:6478–6486
14. Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, Wang Y, MacNeill J, Mitchell J, Gygi SP, Rush J, Polakiewicz RD, Comb MJ (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 105:692–697
15. 1 and peroxisome proliferator-activated receptor γ (PPARγ)/Smad signaling pathways in human liver cancer cells. J Biol Chem 279:44344–44354
16. Han C, Michalopoulos GK, Wu T (2006) Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 207:261–270
17. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K (2001) Transforming growth factor β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with non small cell lung carcinoma. Cancer 91:964–971
18. Hoshiba T, Kawazoe N, Tateishi T, Chen G (2009) Development of stepwise osteogenesis-mimicking matrices for the regulation of mesenchymal stem cell functions. J Biol Chem 284:31164–31173
19. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grünert S (2002) Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 156:299–313
20. Jansson EA, Are A, Greicius G, Kuo IC, Kelly D, Arulampalam V, Pettersson S (2005) The Wnt/β-catenin signaling pathway targets PPARγ activity in colon cancer cells. Proc Natl Acad Sci USA 102:1460–1465
21. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, Standiford TJ (2004) Peroxisome proliferators-activated receptor γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23:100–108
22. Kim ES, Kim MS, Moon A (2005) Transforming growth factor (TGF) β in conjunction with H-ras activation promotes malignant progression of MCF10A breast epithelial cells. Cytokine 29:84–91
23. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, Plunket KD, Shenk JL, Stimmel JB, Therapontos C, Willson TM, Blanchard SG (2002) Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41:6640–6650
24. Min/+ mice. Nat Med 4:1053–1057
25. Lin LC, Hsu SL, Wu CL, Liu WC, Hsueh CM (2011) Peroxisome proliferator-activated receptor γ (PPARγ) plays a critical role in the development of TGFβ resistance of H460 cell. Cell Signal 23:1640–1650
26. Liu M, Yang SC, Sharma S, Luo J, Cui X, Peebles KA, Huang M, Sato M, Ramirez RD, Shay JW, Minna JD, Dubinett SM (2007) EGFR signaling is required for TGFβ1 mediated COX-2 induction in human bronchial epithelial cells. Am J Respir Cell Mol Biol 37:578–588
27. López-González JS, Aguilar-Cázares D, Prado-García H, Nieto-Rodríguez A, Mandoki JJ, Avila-Moreno F, Rivera RM, Chavarría-Garcés J (2002) Lack of correlation between growth inhibition by TGFβ receptor in human non-small cell lung cacinoma cell lines. Lung Cancer 38:149–158
28. Lu D, Carson DA (2010) Repression of β-catenin signaling by PPARγ ligands. Eur J Pharmacol 636:198–202
29. Massagué J (2008) TGFβ in cancer. Cell 134:215–230
30. Navab R, Liu J, Seiden-Long I, Shih W, Li M, Bandarchi B, Chen Y, Lau D, Zu YF, Cescon D, Zhu CQ, Organ S, Ibrahimov E, Ohanessian D, Tsao MS (2009) Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 11:1292–1300
31. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E (1996) TGFβ and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10:2462–2477
32. Oft M, Heider KH, Beug H (1998) TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8:1243–1252
33. Ohta T, Elnemr A, Yamamoto M, Ninomiya I, Fushida S, Nishimura G, Fujimura T, Kitagawa H, Kayahara M, Shimizu K, Yi S, Miwa K (2002) Thiazolidinedione, a peroxisome proliferator-activated receptor ligand, modulates the E-cadherin/β-catenin system in a human pancreatic cancer cell line, BxPC-3. Int J Oncol 21:37–42
34. Puri N, Salgia R (2008) Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog 7:9
35. Rahimi RA, Leof EB (2007) TGFβ signaling: a tale of two responses. J Cell Biochem 102:593–608
36. Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ, Keshamouni VG (2010) Peroxisome proliferator-activated receptor γ activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther 9:3221–3232
37. Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Kim CH, Lee J (2009) Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EFGR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63:219–226
38. Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, Banayo E, Cardiff RD, Izpisua-Belmonte JC, Evans RM (2004) PPARγ signaling exacerbates mammary gland tumor development. Genes Dev 18:528–540
39. Sauvant P, Cansell M, Atgié C (2011) Vitamin A and lipid metabolism: relationship between hepatic stellate cells (HSCs) and adipocytes. J Physiol Biochem 67:487–496
40. Sharma C, Pradeep A, Wong L, Rana A, Rana B (2004) Peroxisome proliferator-activated receptor γ activation can regulate β-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J Biol Chem 279:35583–35594
41. +/− cells. J Cell Sci 118:3247–3261
42. Smith AG, Beaumont KA, Smit DJ, Thurber AE, Cook AL, Boyle GM, Parsons PG, Sturm RA, Muscat GE (2009) PPARγ agonists attenuate proliferation and modulate Wnt/β-catenin signalling in melanoma cells. Int J Biochem Cell Biol 41:844–852
43. Taylor AW (2009) Review of the activation of TGFβ in immunity. J Leukoc Biol 85:29–33
44. Theocharis S, Kanelli H, Politi E, Margeli A, Karkandaris C, Philippides T, Koutselinis A (2002) Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer 36:249–255
45. Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, Clements JL, Sabio G, Davis RJ, Matthews DE, Doble B, Rincon M (2008) Phosphorylation by p38 MAPK as an alternative pathway for GSK3β inactivation. Science 320:667–670
46. + overload indicates early neuronal injury which precedes staining with viability indicators. Brain Res 607:319–323
47. Waaler J, Machon O, von Kries JP, Wilson SR, Lundenes E, Wedlich D, Gradl D, Paulsen JE, Machonova O, Dembinski JL, Dinh H, Krauss S (2011) Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res 71:197–205
48. Wang XQ, Li H, Van Putten V, Winn RA, Heasley LE, Nemenoff RA (2009) Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. Mol Biol Cell 20:791–800
49. Yoshizumi T, Ohta T, Ninomiya I, Terada I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Yi S, Miwa K (2004) Thiazolidinedione, a peroxisome proliferator-activated receptor γ ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 25:631–639
50. Yuan Y, Zhang A, Huang S, Ding G, Chen R (2011) A PPARγ agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling. Am J Physiol Renal Physiol 300:F393–F402